Altimmune (NASDAQ:ALT) Rating Lowered to Sell at Wall Street Zen

Posted by Defense World Staff on Mar 7th, 2026

Altimmune (NASDAQ:ALT – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

ALT has been the topic of a number of other research reports. Citizens Jmp reduced their price objective on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Friday, November 7th. Citigroup restated a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Barclays initiated coverage on shares of Altimmune in a research note on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price objective for the company. Finally, William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Thursday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $16.60.

View Our Latest Report on Altimmune

Altimmune Price Performance

NASDAQ ALT opened at $3.54 on Friday. The business’s fifty day moving average is $4.48 and its 200 day moving average is $4.28. Altimmune has a fifty-two week low of $2.90 and a fifty-two week high of $7.73. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18. The company has a market capitalization of $399.42 million, a PE ratio of -3.50 and a beta of 0.13.

Altimmune (NASDAQ:ALT – Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Altimmune had a negative return on equity of 54.03% and a negative net margin of 214,860.98%.The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.00 million. Sell-side analysts predict that Altimmune will post -1.35 earnings per share for the current year.

Insiders Place Their Bets

In other Altimmune news, Director Jerome Benedict Durso purchased 12,500 shares of the stock in a transaction dated Monday, December 22nd. The stock was acquired at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the acquisition, the director owned 12,500 shares in the company, valued at $51,625. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Gill bought 12,500 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were purchased at an average price of $4.10 per share, with a total value of $51,250.00. Following the completion of the acquisition, the director directly owned 12,500 shares in the company, valued at $51,250. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 30,527 shares of company stock valued at $125,278 in the last ninety days. Insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Altimmune

A number of institutional investors and hedge funds have recently modified their holdings of ALT. Arax Advisory Partners increased its stake in Altimmune by 99.7% in the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after purchasing an additional 4,076 shares during the last quarter. SBI Securities Co. Ltd. lifted its position in shares of Altimmune by 27.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after buying an additional 1,928 shares during the last quarter. Quadrature Capital Ltd acquired a new position in shares of Altimmune in the 4th quarter valued at $36,000. Victory Capital Management Inc. purchased a new position in shares of Altimmune in the 3rd quarter valued at $38,000. Finally, CreativeOne Wealth LLC purchased a new position in shares of Altimmune in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune News Summary

Here are the key news stories impacting Altimmune this week:

Positive Sentiment: Company advanced pemvidutide development — management reiterated plans to initiate a Phase 3 MASH trial in 2026, pemvidutide received FDA Breakthrough Therapy designation for MASH, and RECLAIM Phase 2 topline data in AUD is expected in 3Q 2026. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
Positive Sentiment: Balance sheet strengthened — company reported about $274M in cash, cash equivalents and short-term investments at year-end and completed a $75M registered direct offering in January, supporting clinical programs and runway. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
Positive Sentiment: Company outlined a large, 1,800‑patient Phase III MASH design and signaled cash runway into 2028 as pemvidutide advances — this reduces near-term execution risk for the lead program. Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028
Neutral Sentiment: B. Riley cut its price target from $18 to $13 but kept a Buy rating — the new target still implies meaningful upside vs. current levels, though it reduces analyst enthusiasm relative to prior coverage. Benzinga
Neutral Sentiment: Earnings call and transcripts are available for review — useful for investors who want management’s commentary on timelines, trial designs and cash runway. Altimmune Q4 2025 Earnings Call Transcript (Seeking Alpha)
Neutral Sentiment: Reported short-interest notes appear to show anomalous/zero values in public data feeds and are not a reliable signal at this time.
Negative Sentiment: Q4 earnings missed estimates — EPS of ($0.27) vs. consensus ($0.25) and immaterial GAAP revenue ($0.03M); very large negative margins and negative ROE highlight ongoing R&D spending and lack of commercial revenue. Altimmune stock edges down on fourth quarter earnings miss

About Altimmune

(Get Free Report)

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.